US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tema Oncology ETF
(NQ:
CANC
)
41.35
+0.36 (+0.88%)
Official Closing Price
Updated: 4:15 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tema Oncology ETF
Why Did GLUE Stock Surge Over 50% In Premarket Today?
↗
January 07, 2026
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.
Via
Stocktwits
Tema’s Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance
December 02, 2025
From
Tema ETFs
Via
Business Wire
AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK
↗
November 25, 2025
NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said.
Via
Stocktwits
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
↗
April 25, 2024
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
Healthcare ETFs For The Weight-Loss Drug Boom And Beyond
↗
April 08, 2024
Two dominant investing themes over the past year have been AI and weight-loss drugs.
Via
Talk Markets
Topics
Artificial Intelligence
ETFs
Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will it be a Boost For Pharma Stocks Too?
↗
December 05, 2023
Via
Benzinga
EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads
↗
December 01, 2023
Tema ETFs is redefining thematic investing, focusing on long-term structural trends & precision in security selection rather than chasing short-term fads.
Via
Benzinga
Topics
ETFs
Active ETFs Appear Booming In 2023 — Tema ETFs Are Taking Them Into A New Direction
↗
November 28, 2023
The rapid emergence of the ETF industry, marked by its AuM growth from $1 trillion to $10 trillion this past decade, was driven by passive indexed funds which thrived in a low-rates, low-volatility...
Via
Benzinga
Topics
ETFs
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
↗
November 21, 2023
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,...
Via
Benzinga
Topics
ETFs
